Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users (Q36158848)

12 August 2017

0 references

1 reference

title

Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users (English)

1 reference

Helicobacter pylori infectious disease

12 August 2017

0 references

1 reference

1 reference

1 reference

Vergara M

1

1 reference

12 August 2017

Catalán M

series ordinal

2

1 reference

12 August 2017

Gisbert JP

series ordinal

3

1 reference

12 August 2017

Calvet X

series ordinal

4

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Alimentary Pharmacology & Therapeutics

12 August 2017

1 reference

12 August 2017

21

1 reference

12 August 2017

1411-1418

1 reference

12 August 2017

12

1 reference

Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02444.X

Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02444.X

Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02444.X

Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02444.X

Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02444.X

A method for assessing the quality of a randomized control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02444.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02444.X

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02444.X

Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti‐inflammatory drug users – a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02444.X

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02444.X

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02444.X

Estrategia clínica para la prevención de los efectos adversos sobre el tracto digestivo de los antiinflamatorios no esteroideos

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02444.X

10.1111/J.1365-2036.2005.02444.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference